News

June 6, 2019June 6, 2019

Investigational CFTR Amplifier PTI-428 Receives Orphan Drug Status in Europe

cystic fibrosis, News

Proteostasis Therapeutics received orphan drug designation from the European Commission for its investigational CFTR amplifier PTI-428 in development for the treatment of cystic fibrosis (CF). This recognition of the therapeutic ... Read more

June 5, 2019June 5, 2019

Manuka Honey Could Be Used to Treat CF Lung Infection P. Aeruginosa, Study Suggests

cystic fibrosis, News

Manuka honey, produced from the nectar of a flowering plant native to Australia and New Zealand, showed significant anti-Pseudomonas aeruginosa activity in an experimental model of lung infection designed to ... Read more

June 4, 2019June 4, 2019

Phage Therapy May Help Resolve Multidrug-resistant Pseudomonas Airway Infections, Case Report Suggests

cystic fibrosis, News

Armata Pharmaceuticals‘ investigational phage therapy AP-PA01 combined with antibiotics holds promise for treating multidrug-resistant Pseudomonas airway infections, updated data from a case study show. A young woman with cystic ... Read more

June 3, 2019June 3, 2019

Vertex Plans to Seek Approval of VX-445 Triple Combo in US and Europe

cystic fibrosis, News

Vertex Pharmaceuticals selected its VX-445 (elexacaftor) triple regimen to apply for regulatory approvals in the U.S. and Europe over the third and fourth quarters of 2019. The therapeutic regimen ... Read more

May 31, 2019May 31, 2019

Nitric Oxide Shows Positive Signs in Clearing Hard-to-treat Mycobacterium Lung Infections in CF

cystic fibrosis, News

Inhalation of nitric oxide as an add-on therapy may help reduce the burden of serious bacterial lung infections, namely the hard-to-treat Mycobacterium abscessus, in cystic fibrosis (CF) patients, AIT Therapeutics ... Read more

May 30, 2019May 30, 2019

AffloVest Giveaways Helping to Support CF and Legacy Foundation, International Biophysics Says

cystic fibrosis, News

International Biophysics, the maker of AffloVest, announced that it is continuing to support people with cystic fibrosis and efforts to raise awareness about this disease, donating 50 of its airway ... Read more

May 29, 2019May 29, 2019

ABBV-2222 Partially Corrects CFTR Function in CF Patients, Phase 2 Trials Show

cystic fibrosis, News

Treatment with ABBV-2222, an investigational CFTR corrector formerly known as GLPG2222, was well-tolerated and partially corrected the function of the CFTR protein, both alone and in combination with Kalydeco ... Read more

May 28, 2019May 28, 2019

AzurRx Reaches Enrollment Goal in Trial of Therapy for CF Patients with EPI

cystic fibrosis, News

AzurRx BioPharma has reached its patient enrollment goal in the ongoing Phase 2 trial testing the effectiveness of MS1819-SD, the company’s investigational therapy for the treatment of patients with ... Read more

May 24, 2019May 24, 2019

Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows

cystic fibrosis, News

Long-term treatment with Kalydeco (ivacaftor) is well-tolerated and efficient, with improvements in sweat chloride concentration, growth, and pancreas function maintained over 84 weeks in 2-to-5-year-old children with cystic fibrosis ... Read more

May 23, 2019

31 Days of CF: William’s Story

31 days of CF, News

View this post on Instagram Day 3 of 31 Days of CF ⁣⁣⁣ Topic: Comedy and CF ⁣⁣⁣ ⁣⁣⁣ —⁣⁣⁣ ⁣⁣ ⁣It was a brisk Saturday night ... Read more

Pin It on Pinterest